Product Name: Crizotinib CAS NO: 877399-52-5
Chemical & Physical Properties:
Appearance :white to light yellow powder
Boiling Point:599.2℃ at 760 mmHg
Crizotinib is a targeted therapy drug for non-small cell lung cancer developed by Pfizer in the United States. Its trade name is Xalkori. Xalkori is a cutting-edge and epoch-making drug in the field of lung cancer targeted therapy. It was approved in the United States in August 2011. It was launched on the market and was written into the international lung cancer treatment guidelines at the end of the year as the first-line medication for ALK-positive patients. It is mainly used in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who are positive for anaplastic lymphoma kinase (ALK) determined by the SFDA-approved test method.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.